SAN MARINO, Calif.--()--VG Life Sciences (OTC Pink: VGLS), has received approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the Company’s ongoing physician-initiated Phase 1 clinical trial. The IRB action allows the study to immediately broaden scope to the treatment of all solid tumors, which includes a wide and diverse range of cancer types including breast, colon, lung, liver and pancreas cancer. Effective immediately, principal investigator Dr. Tyler Curiel will begin screening patients with all solid tumors to study the safety of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexevar™ by Bayer AG). VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
“The initial work of Dr. Tyler Curiel utilizing this combination of VG Life Sciences’ compound and sorafenib in ovarian cancer has been very encouraging in terms of its safety. It is just what we expected and we are enthused about expanding this to other cancer types, as well.”
Concurrent with receipt of IRB approval, noted oncologist Dr. Tyler Curiel has announced that he will expand the study of HCQ into patients suffering from relapsed or refractory (drug-resistant) cancers including those of breast, colon, lung, liver and pancreas, and is now screening patients for trial eligibility at the Cancer Therapy and Research Center (CTRC) of the University of Texas Health Sciences Center San Antonio. The protocol for the trial will remain otherwise unchanged, including endpoints, dosing and follow-up evaluation.
VG Life Sciences’ Chief Scientist, Dr. Karen Newell Rogers, commented on the Company’s progress in the clinical trials arena, saying, “The initial work of Dr. Tyler Curiel utilizing this combination of VG Life Sciences’ compound and sorafenib in ovarian cancer has been very encouraging in terms of its safety. It is just what we expected and we are enthused about expanding this to other cancer types, as well.”
Dr. Tyler Curiel, the lead investigator, said, “We now have approval to use sorafenib and HCQ to treat all solid tumors. I have identified candidate patients for this expanded protocol, and we are continuing screening for potential enrollment.”
Dr. Curiel is an internationally recognized expert and speaker in tumor immunology and in the humanities, has been a featured scientist on the NOVANow Science Television program on PBS, and is the recipient of numerous medical and civic service awards including the Mauveny Prize for Cancer Research from Tulane University, the STARS Research Enhancement Award from the University of Texas and the Health Care Hero Award from the San Antonio Business Journal. Dr. Curiel holds membership in a multitude of professional organizations and sits on the Editorial Boards of several publications including The Journal of Immunology and The Journal of Clinical Investigation.
Haig Keledjian, VG Life Sciences’ CEO, said, “We are rapidly progressing through the multiple stages in the validation of our science. Broadening our safety and efficacy studies to include breast, colon, lung, liver and pancreas tumors significantly expands the markets we are working to address, and helps us move closer to bringing effective and efficient treatments, that are more comfortably tolerated, to those seeking treatment for these cancers.”
About VG Life Sciences Inc.
San Marino, California-based VG Life Sciences Inc., formerly known as Viral Genetics, discovers and develops drug therapies from two exclusively licensed platform technologies based on over 60 patents: Metabolic Disruption (MDT) and Targeted Peptides (TPT). A physician-initiated Phase I clinical trial of an MDT compound in combination with Nexavar™ on Stage III and IV ovarian cancer patients is ongoing at the Cancer Therapy and Research Center of The University of Texas Health Science Center at San Antonio. A majority-owned subsidiary, VG Energy (www.vgenergy.net), is dedicated to exploring biofuel and agricultural applications for the MDT platform. Founded in 1994, the biotech company is researching treatments for drug-resistant cancer, Lyme disease, Strep, Staph and Sepsis, and HIV/AIDS. For more information, visit www.vglifesciences.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS:
This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences Inc. from time to time in its periodic reports, including statements about its subsidiary, VG Energy, Inc. None of VG Life Sciences Inc.’s drug compounds are currently approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world, nor are any non-pharmaceutical products of VG Energy, Inc. commercialized. While VG Life Sciences Inc. believes that the forward-looking statements and underlying assumptions are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of VG Life Sciences Inc. to establish the efficacy of any of its drug therapies in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of those drug compounds in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, the successful outcome of such studies or tests, or the successful commercialization of VG Energy, Inc.’s non-pharmaceutical products. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences Inc. will be achieved. VG Life Sciences Inc. disclaims any obligation to update these forward-looking statements, except as required by law.